JP2025515098A - シトクロムbdオキシダーゼ阻害剤およびその使用 - Google Patents
シトクロムbdオキシダーゼ阻害剤およびその使用 Download PDFInfo
- Publication number
- JP2025515098A JP2025515098A JP2024564935A JP2024564935A JP2025515098A JP 2025515098 A JP2025515098 A JP 2025515098A JP 2024564935 A JP2024564935 A JP 2024564935A JP 2024564935 A JP2024564935 A JP 2024564935A JP 2025515098 A JP2025515098 A JP 2025515098A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- independently
- pharma
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263337836P | 2022-05-03 | 2022-05-03 | |
| US63/337,836 | 2022-05-03 | ||
| PCT/US2023/066571 WO2023215803A2 (en) | 2022-05-03 | 2023-05-03 | Cytochrome bd oxidase inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025515098A true JP2025515098A (ja) | 2025-05-13 |
| JP2025515098A5 JP2025515098A5 (cg-RX-API-DMAC7.html) | 2026-05-18 |
Family
ID=88647199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024564935A Pending JP2025515098A (ja) | 2022-05-03 | 2023-05-03 | シトクロムbdオキシダーゼ阻害剤およびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250282784A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4518867A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025515098A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023215803A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117534677B (zh) * | 2024-01-09 | 2024-03-12 | 广东省农业科学院农业质量标准与监测技术研究所 | 一类含亚胺的三环稠合杂环化合物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7569580B2 (en) * | 2004-06-03 | 2009-08-04 | Rigel Pharmaceuticals, Inc. | Heterotricyclic compounds for use as HCV inhibitors |
| CA2599992A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Acridine and quinoline dervatives as sirtuin modulators |
| WO2007144669A1 (en) * | 2006-06-15 | 2007-12-21 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrazolo[1,5-a]quinazolin-5(4h)-ones as inhibitors of poly(adp-ribose)polymerase (parp) |
| GB0701273D0 (en) * | 2007-01-24 | 2007-02-28 | Angeletti P Ist Richerche Bio | New compounds |
| RU2378278C2 (ru) * | 2008-01-24 | 2010-01-10 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 3-СУЛЬФОНИЛ-[1,2,3]ТРИАЗОЛО[1,5-a]ПИРИМИДИНЫ-АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ |
| WO2009151561A2 (en) * | 2008-06-12 | 2009-12-17 | President And Fellows Of Harvard College | Methods and compounds for antimicrobial intervention |
| AU2010295622A1 (en) * | 2009-09-16 | 2012-05-10 | Cylene Pharmaceuticals, Inc. | Tricyclic compounds and pharmaceutical uses thereof |
| WO2018084809A1 (en) * | 2016-11-02 | 2018-05-11 | Nanyang Technological University | Methods for the treatment or prevention of mycobacterial infections |
| JP7659269B2 (ja) * | 2018-12-21 | 2025-04-09 | ユニバーシティ・オブ・ノートル・ダム・デュ・ラック | 抗酸菌症治療のためのbdオキシダーゼ阻害剤の発見 |
| CN113354651B (zh) * | 2020-07-30 | 2022-07-22 | 四川大学 | 吡唑并[1,5-a]喹唑啉衍生物及其在药物制备中的用途 |
| CN117561258A (zh) * | 2021-03-02 | 2024-02-13 | 唯久生物技术(苏州)有限公司 | 作为sos1抑制剂的新型取代的三环氮杂杂环 |
| WO2023287730A1 (en) * | 2021-07-13 | 2023-01-19 | Recurium Ip Holdings, Llc | Tricyclic compounds |
-
2023
- 2023-05-03 US US18/861,826 patent/US20250282784A1/en active Pending
- 2023-05-03 EP EP23800220.8A patent/EP4518867A4/en active Pending
- 2023-05-03 JP JP2024564935A patent/JP2025515098A/ja active Pending
- 2023-05-03 WO PCT/US2023/066571 patent/WO2023215803A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4518867A2 (en) | 2025-03-12 |
| EP4518867A4 (en) | 2026-04-08 |
| WO2023215803A3 (en) | 2023-12-14 |
| US20250282784A1 (en) | 2025-09-11 |
| WO2023215803A2 (en) | 2023-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7644517B2 (ja) | Kras突然変異型タンパク質阻害剤 | |
| US9701681B2 (en) | Fused ring heteroaryl compounds and their use as Trk inhibitors | |
| US7402596B2 (en) | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | |
| WO2020259679A1 (zh) | 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 | |
| US11905247B2 (en) | Compounds as neurokinin-1 receptor antagonists and uses thereof | |
| EP3813834B1 (en) | New crbn modulators | |
| WO2018196677A1 (zh) | 氟代烯丙胺衍生物及其用途 | |
| KR20210107046A (ko) | 거대고리 화합물 및 질환 치료에서 이들의 용도 | |
| JP2022126780A (ja) | ジアリール大員環化合物、医薬組成物及びその用途 | |
| TW202333670A (zh) | 抑制並降解irak4的化合物及其藥物组合物和藥學上的應用 | |
| BR112014030284B1 (pt) | Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| ES2875562T3 (es) | Inhibidores bicíclicos de histona desacetilasa | |
| EP3390374A1 (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| EP3291810B1 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| CN110770242A (zh) | 作为vanin抑制剂的杂芳族化合物 | |
| JP2016503003A (ja) | ナンセンス突然変異抑制剤としてのピリミド[4,5−b]キノリン−4,5(3h,10h)−ジオン | |
| JP7793763B2 (ja) | Tyk2/jak1シュードキナーゼドメイン阻害剤としての化合物ならびに合成および使用方法 | |
| KR20240091048A (ko) | 열 충격 단백질 90 억제제 | |
| TW202328122A (zh) | 降解Bcl-2家族蛋白的化合物及其在醫藥上的應用 | |
| US20210269442A1 (en) | Fused ring derivative used as fgfr4 inhibitor | |
| CN113666922A (zh) | 内磺酰胺化合物及其使用方法 | |
| EP4232431A1 (en) | Compounds and compositions for treating conditions associated with lpa receptor activity | |
| US20250282784A1 (en) | Cytochrome bd oxidase inhibitors and uses thereof | |
| US20190112316A1 (en) | Thiazolo[3,2-a] pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy | |
| KR102941832B1 (ko) | Cdk9 억제제 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260507 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260507 |